Examiner l'évaluation de la qualité : 10 (strong)
Référence: Ghaddaf AA, Aziz M, Alomari MS, Abdulhamid AS, Alharbi FA, Mullah AN, et al. (2021). Influence of aspirin on prevention of colorectal cancer: An updated systematic review and meta-analysis of randomized controlled trials. International Journal of Colorectal Disease, 36(8), 1711-1722.
Lien vers PubMedIn Canada and a number of other countries, ASPIRIN® is a valid registered trade mark of Bayer AG for products containing acetylsalicylic acid or ASA. In such countries it is not permissible to use "aspirin" as the generic name of the drug. Any reference to "aspirin" in any documents accessed through this site that originate outside Canada should therefore be read with this understanding in mind.
PURPOSE: Colorectal cancer is the second most common cause of cancer death worldwide. Aspirin, due to its antineoplastic effects, has been suggested to have chemopreventive effects on colorectal cancer based on recent trials. We conducted this systematic review and meta-analysis to provide an updated evidence about the long-term efficacy of daily aspirin use in the prevention of colorectal cancer.
METHODS: We searched Medline/PubMed, Ovid, Web of Science, and Cochrane Library. We included randomized controlled trials (RCTs) that compared the efficacy of daily aspirin use to placebo in healthy individuals at the time of study entry. The desired outcomes of this review were the incidence of advanced lesions (i.e., adenomas with villous component, adenomas =1 cm in diameter, adenomas with high-grade dysplasia, and/or invasive cancer) and colorectal adenomas.
RESULTS: A total of 15 articles representing 11 RCTs were included. Overall, the results indicated that aspirin significantly reduced the risk of developing colorectal adenomas but not advanced lesions at 3 years (risk ratio (RR) = 0.84, P < 0.05 and risk ratio = 0.82, P = 0.10, respectively). At 5 years, the risk of advanced lesions but not adenomas was reduced by aspirin (RR = 0.68, P < 0.05 and RR = 0.87, P = 0.22, respectively). Aspirin was not found to have an effect on the risk of advanced lesions or adenomas beyond 5 years (hazard ratio (HR) = 0.82, P = 0.07 and HR = 0.99, P = 0.82, respectively).
CONCLUSION: Overall, aspirin (particularly high dose) only reduced the risk of advanced lesions up to 5 years.
adolescents (13-19), adultes (20-59), aînés (60+), cancer, domicile, fournisseur de soins de santé primaires, méta-analyse, modification du comportement